New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma.
Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma. Biology of blood and marrow transplantation Reichardt, V. L., Okada, C. Y., Stockerl-Goldstein, K. E., Bogen, B., Levy, R. 1997; 3 (3): 157-163Abstract
With conventional therapy, multiple myeloma (MM) has a poor prognosis. During the last few years, it has become clear that high-dose chemotherapy with autologous stem cell support can increase overall survival of MM patients, but further improvement in outcome is desperately needed. The monoclonal immunoglobulin (Ig) produced by the MM cells called idiotypes (Id) is a tumor-specific antigen due to unique antigenic determinants that are localized in the variable regions of the Ig molecule. Conceivably, Id immunization of MM patients in complete remission could further increase survival. Here we review the scientific basis for such Id immunization.
View details for PubMedID 9310193